25 May 2013
Keywords: Isis Pharma, Biogen Idec, Spinal muscular atrophy, SMA
Article | 05 January 2012
US biotech firm Biogen Idec (Nasdaq: BIIB) has entered into an exclusive, worldwide option and collaboration agreement with Isis Pharmaceuticals ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 January 2012
24 May 2013
© 2013 thepharmaletter.com